OBJECTIVE - To calculate sustainable generic prices for 4 tyrosine kinase inhibitors (TKIs).
BACKGROUND - TKIs have proven survival benefits in the treatment of several cancers, including chronic myeloid leukaemia, breast, liver, renal and lung cancer.